June 2023
Volume 64, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2023
Acceptability of psychosocial distress screening and referral among patients with primary open-angle glaucoma
Author Affiliations & Notes
  • Samuel Berchuck
    Duke University, Durham, North Carolina, United States
  • Alessandro A Jammal
    Duke University, Durham, North Carolina, United States
  • Tamara J Somers
    Duke University, Durham, North Carolina, United States
  • Felipe A Medeiros
    Duke University, Durham, North Carolina, United States
  • Footnotes
    Commercial Relationships   Samuel Berchuck None; Alessandro Jammal None; Tamara Somers None; Felipe Medeiros Aerie Pharmaceuticals, Allergan, Annexon, Biogen, Carl Zeiss Meditec, Stealth Biotherapeutics, Stuart Therapeutics, Reichert, Code C (Consultant/Contractor), Allergan, Carl Zeiss Meditec, Google Inc., Heidelberg Engineering, Novartis, Reichert, Code F (Financial Support), nGoggle Inc., Code P (Patent)
  • Footnotes
    Support  Supported by National Institute of Health/National Eye Institute grant K99EY033027 (SIB). The funding organizations had no role in the design or conduct of this research.
Investigative Ophthalmology & Visual Science June 2023, Vol.64, OD42. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Samuel Berchuck, Alessandro A Jammal, Tamara J Somers, Felipe A Medeiros; Acceptability of psychosocial distress screening and referral among patients with primary open-angle glaucoma. Invest. Ophthalmol. Vis. Sci. 2023;64(8):OD42.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : In patients with primary open-angle glaucoma (POAG), psychosocial risk factors play an important role in morbidity and mortality. Psychosocial distress screening and referral programs can help to reduce distress; however, they are not currently implemented in glaucoma clinics. Since little is known about the preferences of POAG patients related to distress screening and referral programs, we conducted an acceptability and feasibility study to inform the development of future programs to treat distress in glaucoma.

Methods : We performed a prospective cross-sectional study using POAG patients from the Duke Eye Center from September 2022 to October 2022. Patients were contacted by email two weeks prior to a glaucoma appointment and asked to complete surveys to measure acceptability to distress screening and referral. The acceptability questions are given in Table 1. Distress was measured using the distress thermometer a scale from 0 (no distress) to 10 (high distress). Demographics were self-reported and included race (White, Black/African American, Asian), sex (female vs. male), marital status (married vs. single), and age. Clinical measures included standard automated perimetry (SAP) mean deviation (MD, dB), visual acuity (log MAR) and intraocular pressure (mmHg). Summary statistics are presented along with odds ratios (OR) and p-values from ordinal logistic regression models for each acceptability question.

Results : Our cohort consisted of 47 patients with an average distress thermometer of 3.5 (2.7) and SAP MD of -5.5 (7.6); more summaries are in Table 2. Of the patients, 63% agreed that distress screening would improve their healthcare experience if the results were discussed within the context of their glaucoma (question 3); 66% of patients were interested in a referral to treat their glaucoma related distress (question 5). Only 13% of patients felt that screening would not improve their healthcare experience (question 1). Patients with higher distress were more likely to agree that screening has benefits (OR: 1.42, p-value = 0.005).

Conclusions : Our study indicates that POAG patients are open to a distress screening and referral program in glaucoma clinics. These preliminary results are promising and motivate the need to collect more data related to the preferences of POAG patients toward the identification and treatment of distress related to glaucoma.

This abstract was presented at the 2023 ARVO Annual Meeting, held in New Orleans, LA, April 23-27, 2023.

 

 

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×